drugset / Trial / NCT05013099
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell lung cancer tumors to immuno-oncology therapy.
Timeline
- Start
- 2021-12-09
- Primary completion
- 2025-07
- Completion
- 2025-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ⁸⁹Zr-Df-IAB22M2C | Diagnostic / imaging agent | 1.5 mg | Intravenous |
| Subject | ⁸⁹Zr-Df-IAB22M2C | Diagnostic / imaging agent | 37 mbq | Intravenous |